Compare Indonesia Energy Corporation Limited (INDO) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indonesia Energy Corporation Limited vs Novo Nordisk A/S — how do they compare? Indonesia Energy Corporation Limited trades at $3.03 (market cap $46.01M), while Novo Nordisk A/S trades at $49.6 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 4793.1× Indonesia Energy Corporation Limited's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Indonesia Energy Corporation Limited pays none. Which is the better fit depends on your goals.
| INDO | NVO | |
|---|---|---|
Market Cap | $46.01M | $220.53B |
Sector | Energy | Health |
52-Week High | $6.74 | $71.70 |
52-Week Low | $2.49 | $35.29 |
Enterprise Value | $41.38M | $239.49B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDO trades at $2.99, down 1.32% today, with a bullish technical signal from moving averages and oscillators. The company shows negative profitability metrics including -253.4% net income margin but maintains 100% analyst buy ratings. Recent operational milestones include commencement of drilling at the Kruh Block, providing potential catalysts for future revenue growth.
While current financials show significant losses, analyst optimism and recent operational progress suggest turnaround potential. Key risks include execution challenges in oil exploration and sustained negative cash flow. The stock presents speculative opportunity for investors betting on successful well development and future profitability improvement.
Novo Nordisk (NVO) trades at $49.68, down 1.27% on the day, amid a bullish technical signal from moving averages. The company demonstrates robust fundamentals with a trailing P/E of 12.08 and a net income margin of 37.2%, supported by three consecutive quarterly earnings beats. Recent positive catalysts include EU and Indian regulatory approvals for its oral Wegovy weight-loss pill, expanding its GLP-1 franchise.
The outlook remains positive given strong analyst consensus (57.9% Buy ratings) and projected earnings growth, though risks include intensifying competition in the weight-loss drug market and potential margin pressure. The stock presents a compelling opportunity for investors seeking exposure to a profitable leader in metabolic diseases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
